Brentuximab Vedotin and Crizotinib in Anaplastic Large-Cell Lymphoma
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference33 articles.
1. . A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30 hematologic malignancies.;Bartlett;Blood,2008
2. . A phase II study of SGN-30 (antiCD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.;Forero-Torres;Br J Haematol,2009
3. . Phase III study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkins lymphoma and anaplastic large-cell lymphoma.;Ansell;J Clin Oncol,2007
4. . The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK12 and JunB translation via mTOR signaling.;Staber;Blood,2007
5. . Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.;Zarno;Oncogene,2002
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Synthesis and Reactivity of Masked Organic Sulfates;Chemistry – A European Journal;2024-09-09
2. Evidence-Based Recommendations for Education Provided to Patients and Families Regarding the Adverse Events of ALK and MEK Inhibitors: A Systematic Review From the Children's Oncology Group;Journal of Pediatric Hematology/Oncology Nursing;2024-03
3. Water‐Promoted Synthesis of Pyrazole‐Thiazole‐Derivatives as Potent Antioxidants And their Anti‐cancer Activity: ADMET and SAR Studies;ChemistrySelect;2024-01-18
4. Refractory Anaplastic Large Cell Lymphoma Rescued by the Combination of the Second-Generation ALK Inhibitor Brigatinib, High-dose Chemotherapy and Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature;Clinical Hematology International;2023-04-18
5. Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing;JCO Precision Oncology;2022-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3